COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Running, not enrolling

Conditions studied: Hypertrophic Cardiomyopathy (HCM)

In brief

COLLIGO-HCM is a global observational study that will conduct observational research of hypertrophic cardiomyopathy (HCM) treatment in real-world clinical practice.

Key facts

Study ID

NCT06372457

Run by

Bristol-Myers Squibb

People needed

331

Starts

2023-12-01

Expected to finish

2026-06-30

Last updated by the study team

2026-05-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Source Cohort
• Have at least one recorded encounter with a Hypertrophic Cardiomyopathy (HCM) diagnosis during or after 2018 (the first is defined as the index) and aged ≥18 years on the index date.
• Disease-specific patient history documented in the medical record.
• HCM Sub-Cohort
• Participants in the source cohort with a known HCM diagnosis
• Mavacamten Sub-Cohort - Participants who have their first mavacamten prescription after the index date

You may not qualify if…

• HCM Sub-Cohort
• HCM phenocopy (athlete's heart, hypertensive heart disease, Fabry disease, Pompe disease, Danon disease, amyloidosis) observed after the first observed HCM-associated encounter in the medical record.

Where it is running

• IQVIA — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.